Topical Bevacizumab as Adjunctive Therapy for Bleb Survival after Trabeculectomy in the Rabbit Model
Objective: To determine the effect of topically administered bevacizumab on bleb survival and histology after trabeculectomy in rabbit eyes. Methods: This is an experimental interventional comparative animal study. Sixteen rabbit eyes underwent trabeculectomy, 8 of which were enhanced with intrao...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Philippine Academy of Ophthalmology
2012-12-01
|
| Series: | Philippine Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://paojournal.com/index.php/pjo/article/view/238 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850095598228733952 |
|---|---|
| author | Jaime Rafeal Hubilla Tripon, MD Ma. Imelda Yap-Veloso, MD |
| author_facet | Jaime Rafeal Hubilla Tripon, MD Ma. Imelda Yap-Veloso, MD |
| author_sort | Jaime Rafeal Hubilla Tripon, MD |
| collection | DOAJ |
| description | Objective: To determine the effect of topically administered bevacizumab on bleb survival and histology after trabeculectomy in rabbit eyes.
Methods: This is an experimental interventional comparative animal study. Sixteen rabbit eyes underwent trabeculectomy, 8 of which were enhanced with intraoperative mitomycin-C. Eyes were randomized to receive either topical balanced salt solution (BSS) or topical bevacizumab at a concentration of 12.5 mg/mL. Intraocular pressure, bleb dimensions and vascularity grading were measured. IOP was recorded as a ratio of IOP of the experimental operated eye divided by the IOP of the contralateral control eye (IOPratio) as a function of time. Bleb morphology was recorded as a percentage of the maximum estimated bleb volume (% bleb) as a function of time. Bleb failure occurred if IOPratio ≥0.8, or if % bleb=0. The eyes were then submitted for histopathological analysis after bleb failure has occurred.
Results: In plain trabeculectomy, the mean bleb survival in terms of IOP were 6.3 and 9.2 days in the BSS and topical bevacizumab groups respectively (ρ=0.25). In mitomycin-C-enhanced trabeculectomy, the mean bleb survival was 16 and 18.2 days respectively (ρ=0.40). In plain trabeculectomy, mean bleb survival in terms of bleb morphology were 8 and 12.2 days for the BSS and bevacizumab groups respectively (ρ=0.08). In enhanced trabeculectomy, mean bleb survival were 19.5 and 20 days respectively (ρ=0.99). Mean vascularity grading were 2 and 1.9 for the BSS groups, and 1.6 and 1.4 for the bevacizumab groups.
Conclusion: Topical bevacizumab as adjunctive therapy after trabeculectomy, whether plain or enhanced with mitomycin-C, showed a trend towards prolonged bleb survival, even though the results of this study were not statistically significant. |
| format | Article |
| id | doaj-art-e4e2d7103f5c48a0ada394fd6d75bb60 |
| institution | DOAJ |
| issn | 0031-7659 |
| language | English |
| publishDate | 2012-12-01 |
| publisher | Philippine Academy of Ophthalmology |
| record_format | Article |
| series | Philippine Journal of Ophthalmology |
| spelling | doaj-art-e4e2d7103f5c48a0ada394fd6d75bb602025-08-20T02:41:24ZengPhilippine Academy of OphthalmologyPhilippine Journal of Ophthalmology0031-76592012-12-013726672238Topical Bevacizumab as Adjunctive Therapy for Bleb Survival after Trabeculectomy in the Rabbit ModelJaime Rafeal Hubilla Tripon, MD0Ma. Imelda Yap-Veloso, MD1Department of Ophthalmology and Visual Sciences Philippine General Hospital University of the Philippines Manila Manila, PhilippinesDepartment of Ophthalmology and Visual Sciences Philippine General Hospital University of the Philippines Manila Manila, PhilippinesObjective: To determine the effect of topically administered bevacizumab on bleb survival and histology after trabeculectomy in rabbit eyes. Methods: This is an experimental interventional comparative animal study. Sixteen rabbit eyes underwent trabeculectomy, 8 of which were enhanced with intraoperative mitomycin-C. Eyes were randomized to receive either topical balanced salt solution (BSS) or topical bevacizumab at a concentration of 12.5 mg/mL. Intraocular pressure, bleb dimensions and vascularity grading were measured. IOP was recorded as a ratio of IOP of the experimental operated eye divided by the IOP of the contralateral control eye (IOPratio) as a function of time. Bleb morphology was recorded as a percentage of the maximum estimated bleb volume (% bleb) as a function of time. Bleb failure occurred if IOPratio ≥0.8, or if % bleb=0. The eyes were then submitted for histopathological analysis after bleb failure has occurred. Results: In plain trabeculectomy, the mean bleb survival in terms of IOP were 6.3 and 9.2 days in the BSS and topical bevacizumab groups respectively (ρ=0.25). In mitomycin-C-enhanced trabeculectomy, the mean bleb survival was 16 and 18.2 days respectively (ρ=0.40). In plain trabeculectomy, mean bleb survival in terms of bleb morphology were 8 and 12.2 days for the BSS and bevacizumab groups respectively (ρ=0.08). In enhanced trabeculectomy, mean bleb survival were 19.5 and 20 days respectively (ρ=0.99). Mean vascularity grading were 2 and 1.9 for the BSS groups, and 1.6 and 1.4 for the bevacizumab groups. Conclusion: Topical bevacizumab as adjunctive therapy after trabeculectomy, whether plain or enhanced with mitomycin-C, showed a trend towards prolonged bleb survival, even though the results of this study were not statistically significant.https://paojournal.com/index.php/pjo/article/view/238bevacizumabtrabeculectomyfiltering blebbleb scarringmitomycin-c |
| spellingShingle | Jaime Rafeal Hubilla Tripon, MD Ma. Imelda Yap-Veloso, MD Topical Bevacizumab as Adjunctive Therapy for Bleb Survival after Trabeculectomy in the Rabbit Model Philippine Journal of Ophthalmology bevacizumab trabeculectomy filtering bleb bleb scarring mitomycin-c |
| title | Topical Bevacizumab as Adjunctive Therapy for Bleb Survival after Trabeculectomy in the Rabbit Model |
| title_full | Topical Bevacizumab as Adjunctive Therapy for Bleb Survival after Trabeculectomy in the Rabbit Model |
| title_fullStr | Topical Bevacizumab as Adjunctive Therapy for Bleb Survival after Trabeculectomy in the Rabbit Model |
| title_full_unstemmed | Topical Bevacizumab as Adjunctive Therapy for Bleb Survival after Trabeculectomy in the Rabbit Model |
| title_short | Topical Bevacizumab as Adjunctive Therapy for Bleb Survival after Trabeculectomy in the Rabbit Model |
| title_sort | topical bevacizumab as adjunctive therapy for bleb survival after trabeculectomy in the rabbit model |
| topic | bevacizumab trabeculectomy filtering bleb bleb scarring mitomycin-c |
| url | https://paojournal.com/index.php/pjo/article/view/238 |
| work_keys_str_mv | AT jaimerafealhubillatriponmd topicalbevacizumabasadjunctivetherapyforblebsurvivalaftertrabeculectomyintherabbitmodel AT maimeldayapvelosomd topicalbevacizumabasadjunctivetherapyforblebsurvivalaftertrabeculectomyintherabbitmodel |